Lineage Cell Therapeutics wins US patent for AlloSCOPE 5D cell manufacturing platform, expiry June 2043
LCTX•Patent protection for AlloSCOPE manufacturing platform
Lineage Cell Therapeutics secured U.S. Patent No. 12,692,476 covering its AlloSCOPE manufacturing platform, including AlloSCOPE 5D technology.
Patent protection is expected to run through June 9, 2043.
The platform targets scalable production of genetically stable pluripotent stem cells for large-dose, off-the-shelf cell therapies.
The company positions the 5D approach as combining 2D consistency with 3D bioreactor scale to support commercialization.
